Đang chuẩn bị liên kết để tải về tài liệu:
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Approximately 18–20% of all human breast cancers have overexpressed human epidermal growth factor receptor 2 (HER2). Standard clinical practice is to treat only overexpressed HER2 (HER2+) cancers with targeted anti-HER2 therapies. However, recent analyses of clinical trial data have found evidence that HER2-targeted therapies may benefit a sub-group of breast cancer patients with non-overexpressed HER2. |

TÀI LIỆU LIÊN QUAN

Development of perception test for human-wildlife conflict

TDD & ATDD

Washback of an English achievement test on teachers’ perceptions of professional development at a University in Vietnam

Test Driven Development for Embedded C

Evaluation of test crosses for identification of potential restorers and maintainers for development of rice hybrids (Oryza sativa L.)

BDD in agile testing: An experimental study

Development of a lateral flow immunoassay test strip for the rapid detection of rubella virus

Development and experimental validation of a thermoelectric test bench for laboratory lessons

Test-Driven JavaScript Development

ICT 5 Web Development - Chapter 3.1: Conditional Statements
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.